Freitag, 5. März 2021
Navigation öffnen
Anzeige:
Xospata
 
JOURNAL ONKOLOGIE – STUDIE

CabUC Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Rekrutierend

NCT-Nummer:
NCT04066595

Studienbeginn:
Februar 2020

Letztes Update:
13.02.2020

Wirkstoff:
Cabozantinib

Indikation (Clinical Trials):
Carcinoma, Carcinoma, Transitional Cell

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Johannes Gutenberg University Mainz, Johannes Gutenberg University Mainz

Collaborator:
Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz, Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz

Kontakt

Studienlocations (1 von 1)

Department of Urology of the University Medical Center Mainz
55131 Mainz
(Rheinland-Pfalz)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Regina Loebbecke
E-Mail: regina.loebbecke@unimedizin-mainz.de
» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

In this Phase II study we investigate the benefit of cabozantinib treatment for patients with locally advanced or metastasized urothelial cell carcinoma who have been pre-treated with checkpoint inhibitors only (cohort 1) or who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (cohort 2). We are lacking adequate response and outcome data in patients after immunotherapy and consider that this study will improve future treatment modalities for this important patient cohort.
 

Ein-/Ausschlusskriterien

Inclusion criteria:

1. Ability of subject to understand nature, importance and individual consequences of clinical trial.

2. Signed and dated informed consent of the subject must be available before start of any specific trial procedures.

3. Male or female patients ≥ 18 years

4. Life expectancy ≥ 10 weeks, by judgment of the Investigator.

5. Patients must be able to swallow intact tablets.

6. Patients with histology/cytology confirmed urothelial carcinoma (UC) including mixed pathology with predominantly UC, with locally advanced (T4b) or metastatic (lymph node or visceral) UC arising from bladder or upper urinary tracts. Patients with measurable disease (at least one tumor lesion measurable on radiographic imaging as defined by RECIST 1.1).

7. ECOG (Eastern Cooperative Oncology Group) Performance Status 0-1.

8. Cohort 1: patients who have been pre-treated with checkpoint inhibitors only for one of the following reasons: glomerular filtration rate more ≥30 ml/min and ≤ 60 ml/min (Cockcroft-Gault formula), grade 2 or higher hearing loss or peripheral neuropathy. Cohort 2: patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors.

9. Recurrence within 12 months (by RECIST criteria version 1.1) from last cycle of chemotherapy or PD-1/PD-L1 therapy.

10. Recovery to baseline or ≤ Grade 1 CTCAE v.5.0 from toxicities related to any prior treatments, unless the side effects are clinically non-significant and/or stable on supportive therapy.

Exclusion criteria:

1. Radiation, chemotherapy, or other anti-cancer therapy < 4 weeks prior to enrollment in the study.

2. Patients previously treated with small molecule tyrosine kinase inhibitors.

3. Systemic treatment with radionuclides < 4 weeks prior to enrollment in the study, and subjects with clinically relevant ongoing complications from prior radiation therapy.

4. Abdominal surgery <10 weeks prior to enrollment in the study. Complete wound healing must be observed at least 10 days prior to enrollment, and patients should not have relevant ongoing complications at study enrollment.

5. Inadequate organ and bone marrow function as evidenced by:

1. Hemoglobin <9.0 g/dL;

2. HbA1c > 8%;

3. Absolute neutrophil count <1.5 x 109/L;

4. Platelet count <100 x 109/L;

5. Fasting serum triglycerides > 2.5 x ULN and total cholesterol > 300 mg/dL. Lipid-lowering medication is allowed;

6. AST (aspartate aminotransferase) /SGOT (serum glutamate oxaloacetate transaminase) and/or ALT (alanine aminotransferase)/SGPT (serum glutamate pyruvate transaminase) ≥3.0 x ULN (upper limit of normal);

7. Total bilirubin >1.5 x ULN (upper limit of normal), for subjects with Gilbert's disease > 3 mg/dL;

8. Serum creatinine >2.0 x ULN;

9. Creatinine clearance ≤ 30 mL/min (Cockroft-Gault formula);

10. PT (prothrombin time) or INR (international normalized ratio) or PTT (partial thromboplastin time) ≥ 1.3 x ULN.

11. Urine protein-to-creatinine ratio (UPCR) > 1 mg/mg (> 113.2 mg/mmol)

6. Symptomatic brain metastases or leptomeningeal disease (in case of clinical suspicion of central nervous system involvement confirmed by existing CT or MRI scan of the brain).

7. History of another neoplasm except non-metastatic melanoma skin cancers, carcinoma in situ of the cervix, treated patients with incidental prostate cancer (pT2 (after RPE), Gleason ≤ 6) and PSA (prostate specific antigen) ≤ 0.5 ng/mL, or cancer cured by surgery, small field radiation or chemotherapy <5 years prior to enrollment.

8. History of inflammatory bowel disease, significant bowel obstruction, GI disorder with a high risk of perforation or fistula.

9. Any of the following events within 6 months prior to inclusion: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft surgery, clinically symptomatic and uncontrolled cardiovascular disease, or clinically significant arrhythmias (grade 3-4).

10. Concurrent treatment with strong inhibitors of cytochrome P450 3A4 (including but not limited to cyclosporin, erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil, St John's wort, rifampicin) or patients planning to receive these treatments. For patients who were receiving treatment with such agents, a one-week washout period is required prior to enrollment.

11. Currently receiving any other investigational agent or received an investigational agent within 30 days (or within 5 times the half-life of this agent) before the first dose of cabozantinib.

12. Significant allergy to a pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient.

13. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.

14. Active substance abuse (including active alcohol abuse).

15. Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial.

16. Women who are pregnant or breastfeeding.

17. Women of childbearing potential (WOCBP, a woman is considered of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal (defined as spontaneous amenorrhea for at least a year) or permanently sterilized (e.g. bilateral oophorectomy, hysterectomy, bilateral salpingectomy)), unless they have a negative serum or urine pregnancy test within 7 days prior to first dose of cabozantinib. The minimum sensitivity of the pregnancy test must be 25 IU/L or equivalent units of HCG (human chorionic gonadotropin).

18. Women of childbearing potential, unless they agree to practice a highly effective and medically accepted contraception method during trial and for 4 months after last dose of study drug. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as:

1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

- oral

- intravaginal

- transdermal

2. progestogen-only hormonal contraception associated with inhibition of ovulation:

- oral

- injectable

- implantable

3. intrauterine device (IUD)

4. intrauterine hormone-releasing system (IUS)

5. bilateral tubal occlusion

6. vasectomized partner (medical assessment must be present and done)

7. sexual abstinence when this is in line with the preferred and usual lifestyle of the subject

19. Sexually active male subjects, unless they agree to use contraception (condom, contraception for non-pregnant WOCBP partner) with their partners throughout the study and for 4 months after last dose of study drug and agree to inform the Investigator if the respective partner becomes pregnant during this time.

Studien-Rationale

Primary outcome:

1. Objective response rate after 6 months of cabozantinib treatment (Time Frame - 6 months):
The response rate is defined as the percentage of subjects with a confirmed reduction in tumor size compared to baseline as well as fulfilling the criteria for complete or partial response according to RECIST 1.1. The response to treatment is measured by computer tomography (CT) every 12 weeks starting from the first day of cabozantinib treatment.



Secondary outcome:

1. Progression-free survival (PFS) (Time Frame - Through study completion, up to approximately 2 years):
PFS is defined as the time from first intake of trial medication to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm.

2. 1-year survival (Time Frame - 1 year):
Rate of subjects surviving for at least one year after first intake/dose of trial medication

3. Overall survival (Time Frame - Through study completion, up to approximately 2 years):
The time between first application of trial medication to date of death due to any cause

4. Clinical benefit rate (Time Frame - Through study completion, up to approximately 2 years):
Complete or partial response or stable disease for ≥ 6 months according to RECIST 1.1

5. Response duration (Time Frame - Through study completion, up to approximately 2 years):
Duration of response in months from the first response (CR or PR) to progress after first intake of treatment medication

6. Number of Participants with Adverse Events (AEs) (Time Frame - Through study completion, up to approximately 2 years):
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.

7. Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs) (Time Frame - Through study completion, up to approximately 2 years):
The number of participants who discontinue study treatment due to an AE will be presented.

Geprüfte Regime

  • Cabozantinib (Cabometyx):
    60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Wacken & DKMS: Gemeinsam gegen Blutkrebs

Wacken & DKMS: Gemeinsam gegen Blutkrebs
© DKMS gemeinnützige GmbH

Die DKMS ist zum vierten Mal mit einer Registrierungsaktion Teil des Wacken Open Air Festivals (W:O:A). Vom 3. bis zum 5. August 2017 können sich Besucher nicht nur über die lebensrettende Arbeit der internationalen gemeinnützigen Organisation informieren sondern sich auch als potenzielle Spender aufnehmen lassen. Parallel sind die Unterstützerinnen der Initiative „Wacken hilft“ mit viel Herzblut im Einsatz und verkaufen im Ort selbst gebackenen Kuchen zugunsten der DKMS...

Neue Perspektiven für Frauen mit Eierstockkrebs

In der medikamentösen Behandlung von Frauen mit fortgeschrittenem Eierstockkrebs wurde erstmals nach fast 15 Jahren ein Fortschritt erzielt: Das neue Medikament, ein sogenannter Angiogenesehemmer, greift den Tumor gezielt an und verzögert damit das Fortschreiten der Krebserkrankung. Für die betroffenen Frauen ist dies ein großer Vorteil: Die Therapie ermöglicht ihnen mehr Zeit, die sie – trotz der schweren Erkrankung – weitestgehend beschwerdefrei...

Startschuss für den Regensburger Leukämielauf 2017: Bürgermeisterin Gertrud Maltz-Schwarzfischer übernimmt Schirmherrschaft und die Kapelle Josef Menzl beginnt Training

Startschuss für den Regensburger Leukämielauf 2017: Bürgermeisterin Gertrud Maltz-Schwarzfischer übernimmt Schirmherrschaft und die Kapelle Josef Menzl beginnt Training
© ivanko80 / Fotolia.com

Vor der Kulisse des Alten Rathauses wurde gestern (26.06.) Bürgermeisterin Gertrud Maltz- Schwarzfischer das erste Laufshirt des Regensburger Leukämielaufes 2017 von Professor Dr. Reinhard Andreesen, Vorsitzender der Leukämiehilfe Ostbayern e.V., überreicht. Mit der Übergabe des Laufshirts an das Stadtoberhaupt startet traditionell der Countdown zum größten Benefizlauf in Ostbayern, der in diesem Jahr am 15. Oktober stattfindet.

Brustkrebs: Forscher wollen krankheitsauslösende Gene identifizieren

Brustkrebs: Forscher wollen krankheitsauslösende Gene identifizieren
© Photographee.eu / fotolia.com

Jede zehnte Frau in Deutschland, die an Brustkrebs erkrankt, ist noch keine 45 Jahre alt. Experten vermuten, dass viele der jungen Betroffenen erblich vorbelastet sind: Sie sind Trägerinnen eines oder mehrerer schädlich veränderter Gene, die den Tumor entstehen lassen. Die bereits bekannten Hochrisikogene wie etwa BRCA1 oder BRCA2 sind allerdings nur für höchstens ein Viertel der Fälle bei jungen Frauen verantwortlich. Ein Hamburger Forscherteam macht sich nun...